New study provides unique perspective from the viewpoint of HCPs and patients/caregivers regarding their effectiveness

Possibly the first survey in the EU to evaluate the effectiveness of additional risk minimisation measures (aRMMs) for Bipolar I Disorder, this study treads new ground. It does so, firstly, by adopting a unique viewpoint – that of HCPs, patients and caregivers. And secondly by implementing a web-based survey tool to assess the effectiveness of aRMMs in relation to aripiprazole treatment across 12 EU countries.

Read more ...

Our new paper explores regulatory developments in early access treatments in non US and EU markets

Developing treatments for rare diseases and ensuring these reach patients quickly has long been a regulatory conundrum. Balancing the need for rapid access to promising drugs with those for adequate real world data and safeguards is challenging. In the US and EU, initiatives by the FDA (i.e. BTD) and EMA (i.e. CMA and PRIME) have accelerated developments and arguably served as a broad guide to other regions. Countries such as Brazil, China, India and Russia, for instance, have developed early access programmes and bilateral agreements between regulators, while governments across the globe are increasingly promoting Early Access pathways (EAPs) and Compassionate Use Schemes (CUSs).

Read more ...

Why first-mover advantage is being eroded by disruptive pricing and the consequences for pharma

Although pharmaceutical companies are no strangers to price competition, this has traditionally been around legacy products, not new, first-to-market offerings. As this paper illustrates, however, the pricing environment for new products is being reshaped by intensified competition from fast followers who are bringing rival offers to market more rapidly and, in many cases, at heavily discounted rates. Our analysis of market activity suggests that the rate of discount is related to the goals of new entrants in any given case, be it to overcome inferior clinical value propositions, gain market share quickly, or exploit the potential to be used in multiple follow-on or orphan applications.

Read more ...

Pope Woodhead’s review of market access projects this year highlights two main themes and a host of insights.

Reviewing our projects in 2017, two key market access themes stand out: (a) the challenge of moving from price to value and (b) disrupting the treatment paradigm. And working with clients to overcome challenges in these areas has teased out new lessons and reinforced others. On price to value, for instance, many companies face challenges or need to revisit plans years after launch.

Read more ...

New paper from Pope Woodhead evaluates the potential of digital to drive real patient-centered models

Advanced digital tools promise a smarter, more patient-centric healthcare model in which patients’ data informs developments and outcomes. But can this promise become reality? The signs are encouraging: pharmaceutical companies may have traditionally been behind the curve when it came to adopting digital technologies, but they are increasingly embracing digital platforms.

Read more ...

More Articles ...

Receive Our Newsletter

Please fill out the form below to receive our newsletter. Alternatively email